Clinical Trial Update: S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor [Phase 2]

View source ↗

Summary

A Phase 2 trial of erlotinib for unresectable or metastatic malignant peripheral nerve sheath tumor has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Sarcoma

Drugs mentioned

• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06